Te vac

Pion’s patented μSOL assay was used for kinetic solubility determination. In this assay, the classical saturation shake-flask solubility method was adapted as previously described.^{45 (link)} Test compounds were prepared in 10 mM DMSO stock and diluted to a final drug concentration of 150 μM in the aqueous solution (pH 7.4, 100 mM phosphate buffer). Samples were incubated at room temperature for 6 h and vacuum-filtered using a Tecan Te-Vac to remove any precipitates. The concentration of the compound in the filtrate was measured via UV absorbance (λ: 250–498 nm). The unknown drug concentration was determined by comparing the fully solubilized reference plate that contained 17 μM of the compound dissolved in spectroscopically pure n-propanol. All compounds were tested in duplicate. The kinetic solubility (μg/mL) of compounds was calculated using the μSOL Evolution software (NEED reference). The three controls used were albendazole (low solubility), phenazolpyridine (moderate solubility), and furosemide (high solubility).^{46 (link)}

Pion’s patented μSOL assay was used for kinetic solubility determination.^{11 (link)–13} In this assay, the classical saturation shake-flask solubility method was adapted as previously described by Avdeef et al., 2001.¹³ Test compounds were prepared in 10 mM DMSO stock and diluted to a final drug concentration of 150 μM in the aqueous solution (pH 7.4, 100 mM phosphate buffer). Samples were incubated at room temperature for 6 hours and vacuum-filtered using Tecan TeVac to remove any precipitates. The concentration of the compound in the filtrate was measured via UV absorbance (λ: 250–498 nm). The filtrate drug concentration was determined by comparing the fully solubilized reference plate which contains 17 μM of compound dissolved in spectroscopically pure n-propanol. All compounds were tested in duplicates. The kinetic solubility (μg/mL) of compounds was calculated using the μSOL Evolution software. The three experimental controls used were albendazole (low solubility), phenazolpyridine (moderate solubility) and furosemide (high solubility). The solubility of the three control drugs were measured in each of 380 batches. Albendazole was reported with a solubility of < 1 μg/mL in 324 measurements; furosemide with that of > 55 μg/mL in 378 batches; whereas the solubility of phenazolpyridine was recorded as 27.73 ± 4.49 μg/mL.